Insilico's AI-designed cancer drug ISM6331 reaches first human data: ESMO oral session to report Phase 1 results
Insilico Medicine says the abstract of the first-in-human, multicenter Phase 1 study of ISM6331, a pan-TEAD inhibitor designed and optimized with its generative chemistry platform Chemistry42, is now posted on the 2026 ESMO website, with detailed data due October 25 in a Rapid Oral session in Madrid. The study evaluates safety, tolerability, pharmacokinetics and preliminary antitumor activity in mesothelioma and other advanced solid tumors, including dose-limiting toxicities and a recommended Phase 2 dose. What is public now is the abstract and the session schedule; efficacy remains a question for clinical investigation.